Caliway focuses on breakthrough medical aesthetics and inflammatory medicine of novel small molecule therapeutics with unmet medical needs. Our leading candidate, CBL-514, is a first-in-class new drug that can trigger adipocyte apoptosis at the injection site and effectively reduce subcutaneous fat without causing tissue necrosis or prominent side effects. The results of the CBL514 clinical trial(currently PhIIb) could potentially compete in the more than $100 billion prescription fat reduction market or serve as a complementary treatment for medications like GLP-1. For the same molecule, under a different formulation, CBL-514 is also being developed as a Rare Disorder medication with the current indication for Dercum’s disease and has received Fast Track Designation and Orphanage Drug Designation from FDA(USA) in February 2024.